Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 1/20 | 0.43 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.43 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 4/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | GLS | O94925 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7403833 | 0.83 | ADRB2 (0.44) | CYP3A4L3MBTL1LMNAMEN1KMT2A | |
| SCHEMBL3101339 | 0.83 | TSHR (0.51) | CYP3A4LMNAMEN1KMT2A | |
| SCHEMBL3655864 | 0.82 | HPGD (0.45) | CYP3A4L3MBTL1NAMPTCA1CA2 | |
| SCHEMBL6680706 | 0.82 | ALDH1A1 (0.53) | CYP3A4LMNAMEN1KMT2A | |
| SCHEMBL15385130 | 0.81 | CACNA1H (0.46) | CACNA1HCACNA1BCACNA1CL3MBTL1LMNA | |
| SCHEMBL30600397 | 0.81 | KMT2A (0.45) | CYP3A4L3MBTL1KMT2ANAMPTCA1 | |
| SCHEMBL3654154 | 0.81 | KMT2A (0.45) | CYP3A4L3MBTL1KMT2ANAMPTCA1 | |
| SCHEMBL8650394 | 0.81 | L3MBTL1 (0.42) | L3MBTL1LMNAMEN1KMT2AGRM2 | |
| SCHEMBL24970178 | 0.80 | NOTUM (0.48) | CACNA1HCACNA1BCACNA1CL3MBTL1LMNA | |
| SCHEMBL31142856 | 0.80 | NOTUM (0.48) | CACNA1HCACNA1BCACNA1CL3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921405-B2 | Compounds | OREXO AB (SE) | 2014-12-30 | — | — | US | disclosed |
| US-8921405-B2 | Compounds | OREXO AB (SE) | 2014-12-30 | — | — | US | disclosed |
| EP-2403852-B1 | 2-AMINOBENZIMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INT (DE) | 2014-10-29 | — | — | EP | disclosed |
| CN-102341395-B | 3H-imidazo [4,5-c ] pyridine-6-carboxamides as anti-inflammatory agents | BOEHRINGER INGELHEIM INT | 2014-07-30 | — | — | CN | disclosed |
| US-20130303571-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-14 | — | — | US | disclosed |
| US-20130303571-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-14 | — | — | US | disclosed |
| US-20120196897-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-02 | — | — | US | disclosed |
| US-20120196897-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-02 | — | — | US | disclosed |
| CN-102341395-A | 3H-imidazo [4,5-c ] pyridine-6-carboxamides as anti-inflammatory agents | BOEHRINGER INGELHEIM INT | 2012-02-01 | — | — | CN | disclosed |
| EP-2403852-A1 | 3H-IMIDAZO [4, 5 -C]PYRIDINE- 6 -CARBOXAMIDES AS ANTI- INFLAMMATORY AGENTS | Boehringer Ingelheim International GmbH (DE) | 2012-01-11 | — | — | EP | disclosed |
| US-20100256188-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-07 | — | — | US | disclosed |
| US-20100256188-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-07 | — | — | US | disclosed |
| WO-2010100249-A1 | 3H-IMIDAZO [4, 5 -C] PYRIDINE- 6 -CARBOXAMIDES AS ANTI- INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-10 | — | — | WO | disclosed |
| WO-2010100249-A1 | 3H-IMIDAZO [4, 5 -C] PYRIDINE- 6 -CARBOXAMIDES AS ANTI- INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196897-A1 | NEW COMPOUNDS | MTX1, LTB4R, RDX | CACNA1H 1178/4885CACNA1B 928/4885CACNA1C 649/4885 |
| US-20130303571-A1 | NEW COMPOUNDS | MTX1, LTB4R, RDX | CACNA1H 1178/4885CACNA1B 928/4885CACNA1C 649/4885 |
| US-20100256188-A1 | NEW COMPOUNDS | MTX1, LTB4R, RDX | CACNA1H 1178/4885CACNA1B 928/4885CACNA1C 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.